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Volume 51, Number 11S Abstracts 13Sdata indicates that vascular surgery patients have among the
highest rates of 30-day readmission at 23.9%.
Methods: We retrospectively examined all patients dis-
charged from the vascular surgery service at a single university
hospital over 12 months. We also prospectively followed pa-
tients discharged over one month. 2 tests with Bonferroni
correction were used.
Results: 96 (13%) of the 766 patients discharged
from vascular surgery were readmitted within 30 days.
Of the readmissions, 72 (75%) were unplanned; there-
fore, the unplanned readmission rate was 9%. The most
frequent reasons for unplanned readmission were wound
complications (29%), worsening peripheral arterial dis-
ease (PAD) or nonhealing ulcers (23%), electrolyte dis-
turbance/emergent dialysis (8%), and graft occlusion
(6%). One patient died during readmission. In the pro-
spective study, 13% of patients were readmitted; none
were readmitted to an outside hospital. The presence of
diabetes predicted readmission (p  0.001). Patients
undergoing procedures for PAD (12%) and end stage
renal disease (ESRD) (12%) had a higher (p  .03)
readmission rate than those undergoing procedures for
abdominal aortic aneurysm (4%) or carotid stenosis (4%).
Conclusions: Rehospitalization in vascular surgery pa-
tients can be reduced below rates gleaned from interrogation
of Medicare data. Diabetics and patients undergoing proce-
dures for PAD or ESRD are more likely to be readmitted.
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Author Disclosures: L. Doctor: Nothing to disclose; R. M.
Fairman: Nothing to disclose; B. M. Jackson: Nothing to
disclose;D. Nathan: Nothing to disclose;G. J. Wang: Noth-
ing to disclose; E. Y. Woo: Nothing to disclose.
S4: SVS Plenary Session IV
SS19.
Differential Expression of ERK and Akt Following Nitric
Oxide Exposure in Type 1 and Type 2 Diabetic Rats
Zachary Emond, Vinit Varu, Sadaf Ahanchi, Janet Mar-
tinez, Melina R. Kibbe. Vascular Surgery, Northwestern
University, Chicago, ILObjectives: Diabetic patients develop greater reste-
nosis from neointimal hyperplasia after vascular interven-
tions. Previously, we reported that nitric oxide (NO)
decreased neointimal hyperplasia significantly more in
type 2 diabetic rats than controls, but not at all in type 1
diabetic rats. Given the different insulin levels between
these animal models, and that insulin is known to regu-
late ERK and Akt, we hypothesized that NO differen-
tially effects ERK and Akt activity in type 1 vs type 2
diabetic rats.
Methods: To induce type 2 diabetes, Zucker diabetic
fatty (ZDF) rats were fed Purina 5008 chow. To induce type
1 diabetes, lean Zucker (LZ) rats were injected with strepto-
zotocin (STZ; 60mg/kg). Rats with glucose300mg/dL
were included in the study. Non-STZ LZ rats served as
controls. The carotid artery injury model was performed.
Groups included injury and injuryPROLI/NO (20 mg)
[n6/group].At 14days, phosphorylatedERK(pERK) and
Akt (pAkt) expression was assessed by immunofluorescent
staining.
Results: There were no changes in pERK expression
after NO treatment in LZ control and type 1 diabetic rats
but increased expression in type 2 diabetic rats (44%, p 
0.009). This increase was observedmainly in the adventitia.
pAkt expression decreased in the LZ control (47%, p 
0.012) and type 1 diabetic (51%, p  0.043) rats after NO
treatment but increased in type 2 diabetic rats (53%, p 
0.003). These changes occurred mostly in the neointimal
and adventitia. Interestingly, NO increased the pERK/
pAkt ratio by 29% in the LZ control and 47% in the type 1
diabetic rats but decreased the pERK/pAKT ratio by 12%
in the type 2 diabetic rats.
Conclusions: NO differentially effects the expression
of pERK and pAkt in type 1 vs type 2 diabetic rats, by
decreasing the pERK/pAkt ratio in type 2 diabetic but
increasing this ratio in type 1 diabetic and control rats.
These data suggest one mechanism by which NO inhibits
neointimal hyperplasia in hyperinsulinemic environ-
ments.
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Renal Volume and Blood Pressure Response to Renal
Artery Stenting
J. Gregory Modrall, R. James Valentine, Carlos H. Tima-
ran, Eric B. Rosero, Thomas Anthony, G. Patrick Clagett,
Clayton Trimmer. Surgery, University of Texas Southwest-
ern Medical Center, Dallas, TX
Objectives: The ASTRAL Trial disputed the benefit of
renal artery stenting (RAS) when applied to all hypertensive
patients with renal artery stenoses. However, some patients
may benefit from RAS, and the challenge is to uncover
